ERBB2-associated pulmonary adenocarcinoma
Friday 28 June 2013
HER2-associated lung adenocarcinoma
Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations.
HER2 mutations identify a distinct subset of lung ADCs.
Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2.
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi : 10.1158/1078-0432.CCR-12-0912 PMID: 22761469